Repligen Corporation $RGEN Shares Sold by Raymond James Financial Inc.

Key Points

• Raymond James Financial Inc. reduced its stake in Repligen Corporation by 1.1% during the first quarter, holding 360,760 shares valued at $45.9 million.
• Repligen Corporation reported Q2 earnings of $0.37 per share, missing analysts’ estimates, but revenue increased by 14.8% year-over-year to $182.37 million.
• Brokerages have provided mixed ratings on Repligen's stock, with Barclays issuing an "overweight" rating and a $150.00 price target while others have downgraded their projections.

Raymond James Financial Inc. cut its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 1.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 360,760 shares of the biotechnology company's stock after selling 3,921 shares during the period. Raymond James Financial Inc. owned approximately 0.64% of Repligen worth $45,903,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Raiffeisen Bank International AG acquired a new stake in shares of Repligen during the 4th quarter valued at about $29,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Repligen during the 4th quarter valued at about $40,000. Signaturefd LLC lifted its stake in Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after buying an additional 128 shares in the last quarter. Center for Financial Planning Inc. lifted its stake in Repligen by 110.3% in the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after buying an additional 193 shares in the last quarter. Finally, UMB Bank n.a. lifted its stake in Repligen by 99.4% in the 1st quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock valued at $85,000 after buying an additional 332 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently weighed in on RGEN shares. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a research note on Tuesday, April 29th. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price target on shares of Repligen in a research note on Monday, May 5th. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 price target on the stock in a research note on Tuesday, July 22nd. Evercore ISI decreased their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Repligen has a consensus rating of "Moderate Buy" and a consensus price target of $169.45.

Repligen Trading Down 1.3%

Shares of RGEN stock traded down $1.61 during trading on Wednesday, hitting $118.88. 499,746 shares of the stock traded hands, compared to its average volume of 785,214. The firm has a market capitalization of $6.69 billion, a P/E ratio of -475.50, a price-to-earnings-growth ratio of 2.22 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The firm's fifty day moving average price is $121.58 and its 200-day moving average price is $130.72. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Insider Transactions at Repligen

In other news, Director Martin D. Madaus bought 1,800 shares of the business's stock in a transaction on Friday, August 8th. The shares were bought at an average price of $112.13 per share, with a total value of $201,834.00. Following the completion of the transaction, the director directly owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is currently owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.